Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors

Michail Papamichail, Amir Ali, Michail Pizanias, Praveen Peddu, John Karani, and Nigel Heaton

Institute of Liver Studies, Kings Health Partners at King’s College Hospital NHS Trust, London, United Kingdom

Backgrounds/Aims: Resection or enucleation is currently the treatment of choice for small pancreatic neuroendocrine tumors (NETs). Irreversible electroporation is a novel ablative method that is used for locally advanced pancreatic adenocarcinoma, but little data exists for its use for pancreatic NETs. We report an early experience of IRE for early pancreatic NETs.

Methods: Between April 2014 and March 2015, 3 patients with small (<2 cm) pancreatic NETs were treated with percutaneous IRE.

Results: There were no adverse effects during the procedure. Mean hospital stay was 2.6 days. All patients remained disease free on 12-19 months follow up. One patient developed recurrent pancreatitis with pseudocyst formation.

Conclusions: IRE for small tumors of the pancreas is practical and may offer advantages over other thermal ablative techniques, since it preserves vital structures such as blood vessels, bile and pancreatic ducts. Further data regarding the long term disease free interval is required to establish efficacy.

Key Words: Irreversible electroporation (IRE); Pancreatic neuroendocrine tumors; Non-thermal ablation

INTRODUCTION

Pancreatic neuroendocrine tumors (NETs) are rare neoplasms that arise in the endocrine tissues of the pancreas and account for <3% of all primary pancreatic tumors. Most pancreatic NETs are sporadic, but may be associated with hereditary endocrinopathies. The reported annual incidence ranges between 0.32-0.43/100,000, but has risen recently due to increased detection of asymptomatic disease on cross-sectional imaging. The majority are non-functional and present with non-specific symptoms or are asymptomatic. Peptide hypersecretion from pancreatic NETs occasionally presents with a hormonal syndrome. In general, they are associated with relatively good survival, although significant variability in outcomes may be seen, based on biological heterogeneity.

Functional status, tumor localization, histological grade and TNM classification are all important factors determining treatment strategy. Small (<1-2 cm) locoregional, well-differentiated tumors with favourable imaging characteristics, have low metastatic potential and surgical resection alone usually offers excellent results.

Conventional thermal ablative techniques such as radio-frequency ablation (RFA) and microwave ablation (MWA) can be used to treat pancreatic tumours, but there is a risk of thermal injury to the pancreatic duct and surrounding structures including the superior mesenteric artery (SMA), superior mesenteric vein (SMV), and duodenum.

Irreversible electroporation (IRE) is a novel non-thermal ablative therapy that is used primarily for treating liver tumors and pancreatic adenocarcinomas not amenable to resection or conventional ablation due to close proximity to major vascular or vital structures such as the bile duct or the pancreatic duct. Its principle is based on the delivery of short-pulsed high-voltage electric current through electrodes positioned adjacent to the tumor causing irreversible injury to cell membrane and cell death by apoptosis. For tumors located in the pancreas, it has been used for treatment of the non-metastatic locally ad-
Table 1. The characteristics of patients

| Patient No | Age at presentation | Size of pancreatic NET (mm) | Location | Symptoms | Interval to IRE from diagnosis | Complications | Follow up |
|------------|---------------------|-----------------------------|----------|----------|------------------------------|---------------|----------|
| 1          | 29                  | 9                           | Head     | Hypoglycaemic episodes       | 11 months     | Recurrent mild pancreatitis with pseudocyst formation | No recurrence after 14 months |
| 2          | 66                  | 10                          | Head/neck| Non-specific upper abdominal symptoms | 10 months     | None                              | No recurrence after 19 months |
| 3          | 64                  | 18                          | Uncinate process | Episode of abdominal pain and sepsis | 9 months     | None                              | No recurrence after 12 months |

NET, neuroendocrine tumor; IRE, irreversible electroporation

vanced ductal adenocarcinoma following Folfirinox neo-
adjuvant chemotherapy and/or radiation, with the intention of achieving disease control.\textsuperscript{12,13}

Experience with this technique is available for locally advanced pancreatic cancer, but currently no available data exists on Medline for the use of IRE in pancreatic NETs. We presented 3 patients with one functioning and 2 non-functioning pancreatic NETs treated with IRE and discuss potential indications, complications and outcomes of this modality.

**MATERIALS AND METHODS**

Between April 2014 and March 2015, 3 patients underwent IRE for pancreatic neuroendocrine tumors (Table 1). The first patient presented with frequent hypoglycaemic episodes, elevated serum insulin but normal C-peptide (636 pmol/L range 298-2350). Computed tomography (CT) and magnetic resonance imaging (MRI) showed a 9 mm-sized enhancing lesion at the head of the pancreas consistent with NET (Fig. 1A). Octreotide scan was negative and endoscopic ultrasonography (EUS) with fine needle aspiration (FNA) of the lesion was performed. Histology showed features of NET, but due to insufficient sample, tests for NET markers or mitotic index were not done. A diagnosis of benign insulinoma was made, and conservative management with observation was offered in the first instance. The tumor remained stable over a period of 10 months, but the symptoms persisted. Treatment options including IRE were discussed with the patient and a decision was made to proceed with IRE.

The second patient was investigated for nonspecific abdominal discomfort and indigestion and found to have a 10 mm-sized lesion with neuroendocrine features at the junction of the head and neck of the pancreas in close proximity with the SMV. Octreotide scan and biochemical

![Figure 1](image1.png)
neuroendocrine screen tests were both negative, but a diagnosis of pancreatic NET was corroborated by EUS findings. After a period of observation in which the tumor characteristics were unchanged, a decision was made to treat with IRE instead of pancreatoduodenectomy with possible SMV resection.

The third patient presented with an episode of abdominal pain and biliary sepsis on background of diffuse cholangiopathy, and a history of gallstones pancreatitis. An incidental finding on CT imaging was an 18 mm-sized NET in the uncinate process of the pancreas. The diagnosis was confirmed with EUS and positron emission tomography (PET) scan. The biochemical neuroendocrine screen was negative, and the patient was managed conservatively. The size of tumor was unchanged over a period of 9 months. Cholangitis resolved with antibiotic therapy. Following further discussion, IRE was offered.

**RESULTS**

The decision to proceed to treatment with IRE was made after multidisciplinary team discussion and patient choice and approval from the New and Novel Procedure Committee from our institution was obtained. IRE (Nanoknife system, Angiodynamics, Lanthan, NY, USA) was performed percutaneously with CT guidance under general anaesthesia. There were no adverse effects during the procedure. In the first two patients, 2 electrodes were used and in the 3rd patient one additional electrode was required due to the size of tumor (Fig. 1B). Delivery of 180 pulses at 2500-3000 watts was given to each patient. Mean hospital stay was 2.6 days. The patient with insulinoma developed mild pancreatitis after procedure, which was treated conservatively. A further episode of pancreatitis was associated with a 13 cm-sized pseudocyst in the head of the pancreas. Despite the size of the cyst, the patient had limited symptoms and the fluid resolved without any intervention 4 months later (Fig. 2A and 2B). No complications were reported for the other 2 patients. Follow up at 12, 14 and 19 months with CT and MRI confirmed satisfactory ablation with no evidence of recurrence in all 3 patients (Fig. 1C and 1D). Resolution of symptoms occurred in the patient with the insulinoma, but the non-specific symptoms of the second patient did not change. The third patient continued to be monitored for cholangiopathy.

**DISCUSSION**

Pancreatic NETs are a diverse group of neoplasms, with low prevalence and relatively slow progression, but strong metastatic potential. Surgical resection is currently the mainstay of treatment of the pancreatic NET even in the presence of metastatic disease. Clinical data supports the prospect of improved outcome when primary tumor is resected. Small tumors (<1-2 cm) are associated with an excellent prognosis and depending on their location, enucleation rather than more radical surgery may suffice. Other studies have suggested that non-functional asymptomatic tumors <10 mm may be safely removed.
Table 2. Potential indications for irreversible electroporation treatment in early stage pancreatic neuroendocrine tumors

- Size < 1-2 cm
- No evidence of regional lymphadenopathy or distant metastasis
- Surgically unfit patient
- Low histological grade
- Benign imaging characteristics
- Symptomatic non-responsive to medical treatment
- Anatomic location (tumor in close proximity to the superior mesenteric artery and or portal vein)
- Patient choice

observed.\textsuperscript{16,17} If surgery of higher risk is considered, the option outweighs the benefit in an unfit patient. Similarly, in benign symptomatic cases (e.g., insulinoma) non-responsive to medical treatment, surgery could be avoided and ablation may be considered instead.

Ablative methods used in the pancreatic tumors, include RFA/MWA, cryoablation, photodynamic therapy, ethanol/chemotherapeutic agent injection, high intensity focused ultrasound (HIFU) and IRE.\textsuperscript{18-20} Indications include inoperable, locally advanced pancreatic adenocarcinoma and less commonly premalignant cystic and solid lesions of the pancreas.\textsuperscript{18-20} EUS-guided ethanol ablation therapy for treatment of the pancreatic NETs is associated with significant co-morbidities with a 61% response rate. Improvements in ablative therapies continue and more data are required.\textsuperscript{21,22} Percutaneous and endoscopic RFA has also been used, but the thermal injury associated with this technique limits its use.\textsuperscript{23,24}

IRE is a novel ablative technology that uses high-voltage electric pulses directed to tumor cells resulting in creation of nano-pores within the phospholipid bilayer of cell membrane, ultimately inducing apoptotic cell death.\textsuperscript{20,25,26} It is considered superior to other ablative methods because little thermal energy is generated, underlying extracellular matrix is unaffected and adjacent vital structures such as vessels, nerves or ducts can be preserved.\textsuperscript{25-27} The electrodes can be placed either percutaneously or during laparotomy/ laparoscopy. Absolute contraindications include cardiac arrhythmias or implanted pacemakers/defibrillators.\textsuperscript{27,28}

The experience of IRE in the locally advanced, non-metastatic pancreatic cancer has shown potential benefit in locoregional palliation and overall survival, symptomatic improvement and even augmentation of the surgical margins for concomitant or subsequent curative resection.\textsuperscript{10,29} Reported IRE-related complications include bleeding, bile/pancreatic leak, portal vein thrombosis, duodenal perforation (transduodenal electrode placement), pancreatitis, and cardiac arrhythmias.\textsuperscript{30} A lower complication rate was observed with the use of percutaneous IRE (9% vs. 15%). IRE-related mortality was 3% and 0% for open and percutaneous approaches, respectively. These data suggest that IRE is a relatively low-risk procedure and can safely be used in circumstances where surgery and other ablative methods are contraindicated.\textsuperscript{18,29-31}

There is little available data on the use of this modality in the treatment of less aggressive pancreatic neoplasms such as NETs. This small pilot study shows that this form of locoregional therapy offers a novel approach to patients with small NETs of the pancreas or for surgically unfit patients with tumors < 3 cm in diameter (Table 2).

The three cases in our study had small, low grade tumors with favorable imaging characteristics. Patients were treated following permission from the hospital novel procedures committee and informed discussion. No recurrence was observed on 12-19 months follow-up and the patient with a hormonal syndrome (insulinoma) had resolution of symptoms. Acute pancreatitis is a well-known complication of this method, and treatment does not differ from standard guidelines. In our study, the patient with the large pseudocyst was treated conservatively with significant resolution of the cyst, and is currently totally asymptomatic. The possibility of establishing a clinical trial to evaluate IRE against traditional surgical resection or enucleation deserves wider consideration.

REFERENCES

1. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1766-1773.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE,
et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
3. Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNE): tumor detection, staging, prognosis, and response to treatment. Acta Radiol 2016;57:260-270.
4. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007;11:1460-1467.
5. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247:490-500.
6. Nissen NN, Kim AS, Yu R, Wolin EM, Friedman ML, Lo SK, et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg 2009;75:1025-1029.
7. Chuang CC, Bhurke S, Chen SY, Brulais S, Gabriel S. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ 2015;18:126-136.
8. Ito T, Lee H, Hijioka M, Kawabe K, Kato M, Nakamura K, et al. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan. J Hepatobiliary Pancreat Sci 2015;22:574-577.
9. Klimstra DS, Beltran H, Lilienbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book 2015:92-103.
10. Cherenfant J, Stocker SI, Gage MK, Du H, Thurow TA, Odelaye M, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery 2013;154:785-791.
11. Dunki-Jacobs EM, Philips P, Martin RC 2nd. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 2014;218:179-187.
12. Weiss MJ, Wolfgang CL. Irreversible electroporation: a novel pancreatic cancer therapy. Curr Probil Cancer 2013;37:262-265.
13. Kwon D, McFarland K, Velanovich V, Martin RC 2nd. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery 2014;156:910-920.
14. Doi R. Determinants of surgical resection for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2015;22:610-617.
15. Vinik A, Casellini C, Perry RR, Feliberti E, Vingan H. Diagnosis and management of pancreatic neuroendocrine tumors (PNETs). In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al. ed. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc., 2000.
16. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Figler JL, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 2012;152:965-974.
17. Strosberg JR, Cheema A, Kvols LK, Stage I nonfunctioning neuroendocrine tumors of the pancreas: surgery or surveillance? J Clin Oncol 2011;29(Suppl 4):349.
18. Romboius SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg 2015;102:182-193.
19. Keane MG, Bramis K, Pereira SP, Fusiak GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol 2014;20:2267-2278.
20. Ierardi AM, Lucchina N, Petritto M, Floridi C, Piacentino F, Bucuzzi A, et al. Systematic review of minimally invasive ablation treatment for locally advanced pancreatic cancer. Radiol Med 2014;119:483-498.
21. Park do H, Choi JH, Oh D, Lee SS, Seo DW, Lee SK, et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc 2015;48:158-164.
22. Zhang WY, Li ZS, Jin ZD. Endoscopic ultrasound-guided ethanol ablation therapy for tumors. World J Gastroenterol 2013;19:3397-3403.
23. Rossi S, Viera FT, Ghiton G, Cobiainchi L, Rosa LL, Sicilliani L, et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014;43:938-945.
24. Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cincinni VR, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015;7:52-59.
25. Scheffer HJ, Melenhorst MC, Vogel JA, van Tilborg AA, Nielsen K, Kazeremt G, et al. Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma using the dorsal approach: a case report. Cardiovasc Interv Radiol 2015;38:760-765.
26. Philips P, Hays D, Martin RC. Irreversible electroporation ablation (IRE) of unreatable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS One 2013;8:e76260.
27. Piaelli S, Butturini G, Frigerio I, Salvia R, Armatura G, Barcchion M, et al. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg 2015;32:90-97.
28. Nielsen K, Scheffer HJ, Vieveen JM, van Tilborg AA, Meijer S, van Kuijk C, et al. Anaesthetic management during open and percutaneous irreversible electroporation. Br J Anaesth 2014;113:985-992.
29. Moir J, White SA, French JJ, Littler P, Manas DM. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol 2014;40:1598-1604.
30. Martin RC 2nd, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013;20 Suppl 3:S443-S439.
31. Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingsone AS, et al. Percutaneous irreversible electroporation for downstaging and control of unreatable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012;23:1613-1621.